Loading...
Market
How much will Gilead pay in milestones to Tubulis by end of 2025?
3
Resolution / Starting Odds
$0 • 25%
$1 to $100 million • 25%
$101 to $250 million • 25%
Over $250 million • 25%
Financial disclosures from Gilead Sciences or Tubulis
Story
Gilead and Tubulis Sign $20M ADC Agreement for Solid Tumors with $30M Opt-in Fee and $415M Milestones
Dec 3, 2024, 12:54 PM
Gilead Sciences Inc. has entered into an exclusive option and license agreement with Tubulis to develop an antibody-drug conjugate (ADC) candidate targeting select solid tumors. The agreement includes an upfront payment of $20 million, a $30 million opt-in fee, and potential milestone payments totaling up to $415 million, along with mid-single to low double-digit tiered royalties. The specific target of the ADC has not been disclosed, but it is indicated that it will be a Topoisomerase I (TopoI) ADC.
View original story
Similar markets
Less than €100 million • 33%
Between €100 million and €500 million • 33%
More than €500 million • 33%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Less than €100 million • 25%
€100 million to €200 million • 25%
€200 million to €300 million • 25%
More than €300 million • 25%
Less than $100B • 25%
$100B to $150B • 25%
$150B to $200B • 25%
More than $200B • 25%
None • 25%
Up to $100M • 25%
$100M to $200M • 25%
Over $200M • 25%
Yes • 50%
No • 50%
Full $1.5 billion • 25%
$1.25 - $1.5 billion • 25%
$1 - $1.25 billion • 25%
Below $1 billion • 25%
